Cargando…

A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

PURPOSE: Platinum-based chemotherapy, consisting of etoposide and cisplatin (EP), has been the cornerstone of therapy for extensive-stage small-cell lung cancer (ES-SCLC) for decades. Despite the marked initial sensitivity of SCLC to chemotherapy, EP regimens cannot avoid the emergence of drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Zhengang, Lin, Anqi, Li, Kun, Lin, Weiyin, Wang, Qiongyao, Wei, Ting, Zhu, Weiliang, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594009/ https://www.ncbi.nlm.nih.gov/pubmed/31417239 http://dx.doi.org/10.2147/DDDT.S205633

Ejemplares similares

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

High mutations in fatty acid metabolism contribute to a better prognosis of small‐cell lung cancer patients treated with chemotherapy
por: Lyu, Qiong, et al.
Publicado: (2021)

CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Yi, Yonglin, et al.
Publicado: (2022)

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
por: Yao, Zifu, et al.
Publicado: (2022)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian
por: Lin, Anqi, et al.
Publicado: (2022)

METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy
por: Sun, Yueqin, et al.
Publicado: (2023)

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
por: Lin, Anqi, et al.
Publicado: (2019)

CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter
por: Qiu, Zhengang, et al.
Publicado: (2019)

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer
por: Li, Man, et al.
Publicado: (2020)

FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide
por: Ma, Jian, et al.
Publicado: (2017)

NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the P62 protein in the autophagy process
por: Shen, Weitao, et al.
Publicado: (2022)

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
por: Yi, Ruibin, et al.
Publicado: (2022)

Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer
por: Schenk, Maximilian W., et al.
Publicado: (2021)

Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions
por: Rezonja, Renata, et al.
Publicado: (2013)

Dual Peptide-Modified Nanoparticles Improve Combination Chemotherapy of Etoposide and siPIK3CA Against Drug-Resistant Small Cell Lung Carcinoma
por: Huang, Hsin-Lin, et al.
Publicado: (2020)

An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
por: Doyle, L. A., et al.
Publicado: (1995)

Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study
por: Dai, Yi-Jun, et al.
Publicado: (2023)

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.
por: Gogas, H., et al.
Publicado: (1997)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Combination of Near Infrared Light-Activated Photodynamic Therapy Mediated by Indocyanine Green with Etoposide to Treat Non-Small-Cell Lung Cancer
por: Luo, Ting, et al.
Publicado: (2017)

Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells
por: Dong, Qi, et al.
Publicado: (2020)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
por: Jensen, P. B., et al.
Publicado: (1993)

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.
por: Lee, C. R., et al.
Publicado: (1993)

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer
por: Gu, Liyan, et al.
Publicado: (2019)

Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes
por: Yang, Qi, et al.
Publicado: (2021)

Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial
por: Shi, Yuankai, et al.
Publicado: (2015)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL
por: Vaculova, Alena, et al.
Publicado: (2010)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

Case Report: Etoposide-nedaplatin induced rhabdomyolysis in a small cell lung cancer patient
por: Xu, Xiaohu, et al.
Publicado: (2023)

MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients
por: Wu, Longqiu, et al.
Publicado: (2022)

A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis
por: Li, Yimin, et al.
Publicado: (2020)

Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity
por: Ye, Taojun, et al.
Publicado: (2023)

Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients
por: Lin, Anqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0sd84qhlrqmfoindq7u1de7o3p